Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GFER | P55789 | 2/20 | 0.55 |
| ▸ | CASP6 | P55212 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 2/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | RORC | P51449 | 14/20 | 0.48 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.48 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | RORA | P35398 | 1/20 | 0.46 |
| ▸ | RORB | Q92753 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17002237 | 0.83 | GFER (0.62) | GFERCASP6MAPTMEN1KMT2A | |
| SCHEMBL26870441 | 0.81 | GFER (0.55) | GFERCASP6MAPTMEN1KMT2A | |
| SCHEMBL30129212 | 0.81 | GFER (0.55) | GFERCASP6MAPTMEN1KMT2A | |
| SCHEMBL15055481 | 0.81 | CASP6 (0.51) | GFERCASP6MAPTMEN1KMT2A | |
| SCHEMBL8320029 | 0.81 | ALK (0.55) | GFERCASP6MAPTRORCKDM4E | |
| SCHEMBL2768112 | 0.80 | HTR1A (0.45) | MAPTKMT2ARORCKDM4EGAA | |
| SCHEMBL5256454 | 0.80 | MAPT (0.56) | MAPTMEN1KMT2APDK2SMN1; SMN2 | |
| SCHEMBL2474621 | 0.80 | SIRT6 (0.53) | GFERMAPTMEN1KMT2APDK2 | |
| SCHEMBL24196346 | 0.80 | GFER (0.62) | GFERCASP6MAPTMEN1KMT2A | |
| SCHEMBL22914838 | 0.80 | ENPP2 (0.53) | GFERCASP6MAPTMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1592426-B1 | 2-CYANOPYRROLOPYRIMIDINES AND PHARMACEUTICAL USES THEREOF | NOVARTIS AG (CH) | 2007-12-19 | — | — | EP | disclosed |
| US-20060247251-A1 | 2-Cyanopyrrolopyrimidines and pharmaceutical uses thereof | NOVARTIS AG (CH) | 2006-11-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060247251-A1 | 2-Cyanopyrrolopyrimidines and pharmaceutical uses thereof | DPYD, P2RY1, P2RY2 | GFER 2244/4885CASP6 2723/4885MAPT 2788/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.